95 results about "Plasmodium sp" patented technology

The invention provides a plasmodium real-time detection method based on a lightweight neural network model. The plasmodium real-time detection method comprises the steps of obtaining a blood smear image data set and performing preprocessing; establishing a lightweight plasmodium detection model based on a deep learning algorithm; inputting the preprocessed blood smear image data set into a plasmodium detection model for iterative training; performing plasmodium detection on a to-be-detected blood smear image by using the trained plasmodium detection model; according to the method, a lightweight detection model is constructed based on a deep learning algorithm, so that high-precision plasmodium detection is realized, and the real-time performance of detection is effectively improved; meanwhile, the lightweight model design can adapt to a low-resource environment, so that the model can efficiently run on low-power-consumption equipment, and automatic real-time malaria detection requirements in remote areas and low-resource areas are met; in addition, various forms and life cycle stages of the plasmodium can be accurately identified, and the detection comprehensiveness is improved.

The invention provides a method for simultaneously detecting three hematogenous parasites based on RAA-LFS and application of the method. The method comprises the following steps: firstly, screening target genes of genomic DNA of specific amplified toxoplasma gondii, babesia and plasmodium and primers of the target genes; a primer and probe combination for specifically amplifying the 18s rRNA-1 gene of the toxoplasma gondii, the 18s rRNA-2 gene of the babesia and the 18s rRNA-3 gene of the plasmodium is determined; rapid multiple detection is completed in a reaction system by utilizing an RAA constant-temperature amplification technology, and a detection result is intuitively judged by combining a lateral flow chromatography test strip, so that the detection efficiency is greatly improved, and the result can be obtained in a short time. The RAA-LFS detection method provided by the invention has remarkable advantages in application scenes such as epidemic disease prevention and control or blood screening.

The present invention provides methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for the possible inhibition of plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

This invention belongs to the field of organic synthetic chemistry technology, specifically relating to a selenium-based indoloquinazoline derivative, its preparation method, and its application, comprising: in an organic solvent, using aromatic amine compounds, malononitrile, and diselenoether as raw materials, in the presence of a palladium catalyst and an organic base, at 90°C... o The reaction was carried out under C conditions with stirring to obtain a selenyl indoline quinazoline derivative. This method features mild reaction conditions, simple operation, high yield, and good functional group compatibility, conforming to the principles of green chemistry. Furthermore, the selenyl indoline quinazoline derivative provided by this invention exhibits good inhibitory activity against Plasmodium, providing a drug lead compound for the development of novel antimalarial drugs and holding significant importance for the prevention and / or treatment of malaria.

An immunogenic composition comprising: a) one or more Plasmodium-derived ribosomal or ribosomal associated protein or immunogenic fragment thereof which has a sequence which is at least about 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to a ribosomal or ribosomal associated protein or an immunogenic fragment of a ribosomal or ribosomal associated protein recited in FIG. 1; or a ribosomal or ribosomal associated protein or peptide or immunogenic fragment thereof as recited in FIG. 2 or FIG. 3; and / or b) a polynucleotide encoding one or more protein, peptide or immunogenic fragment of a); wherein the immunogenic composition is for use in eliciting an immune response in a subject to treat or prevent malaria. Also provided are Plasmodium-derived ETRAMPs and / or histones, or immunogenic fragments thereof, for use in eliciting an immune response in a subject, preferably to treat or prevent malaria.

A chimeric or fusion protein for inducing an immune response against P. gingivalis, the protein comprising a first polypeptide linked to a second polypeptide, wherein A) the first polypeptide comprises or consists of the amino acid sequence of an active site of Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto, and B) the second polypeptide comprises or consists of the amino acid sequence of an adhesin domain of Arg- or Lys-gingipain of P. gingivalis, the second polypeptide a) preferably does not comprise part or all of the sequence of a truncated adhesin domain (CAD), and / or b) comprises an amino acid sequence that corresponds substantially to the full length of the DUF2436 domain of Arg- or Lys-gingipain, or a sequence that is at least 80% identical thereto.

The present invention relates to ssDNA aptamers speciically binding to Plasmodium lactate dehydrogenase (LDH). The invention provides ssDNA aptamers having the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 2, which are capable of binding LDH from at least Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae. The aptamers enable in vitro detection of malaria independently of the infecting Plasmodium species and may be used in diagnostic compositions, kits, and biosensor-based detection systems.

The invention provides a composition comprising a Plasmodium species multimeric protein capable of forming a nanoparticle and at least one antigen of interest, wherein the multimeric protein comprises a monomer chosen from Plasmodium species pyridoxal 5'-phosphate synthase (PLP), chaperone 60 protein (Cpn60), and caseinolytic protease (Clp). In embodiments, the invention provides the composition wherein the monomers assemble to form a multimeric nanoparticle and / or which comprises an adjuvant. The invention further provides a nucleic acid encoding the multimeric protein and the at least one antigen of interest, E. coli comprising the nucleic acid, and the use of such in a method for producing the inventive multimeric protein and the at least one antigen of interest. Also provided are a method and use of the inventive multimeric protein and the at least one antigen of interest for immunizing a subject against Plasmodium species.

This invention provides a method for simultaneous detection of three bloodborne parasites based on RAA-LFS and its applications. First, target genes and primers for specifically amplifying the genomic DNA of Toxoplasma gondii, Babesia, and Plasmodium are screened, identifying primer and probe combinations specifically for amplifying the 18S rRNA-1 gene of Toxoplasma gondii, the 18S rRNA-2 gene of Babesia, and the 18S rRNA-3 gene of Plasmodium. Using RAA isothermal amplification technology, rapid multiplex detection is achieved in a single reaction system. Combined with lateral flow chromatography test strips for intuitive result interpretation, detection efficiency is greatly improved, and results are obtained in a short time. The RAA-LFS detection method provided by this invention has significant advantages in applications such as epidemic prevention and control or blood screening.

The invention relates to chimeric Plasmodium antigenic polypeptides derived from pre-erythrocytic (PE) antigens and associated in a fusion polypeptide. In particular, the invention relates to antigenic fusion polypeptides of malaria parasites wherein said antigenic polypeptides exhibit a protective effect, especially that of eliciting a protective immune response in a host against challenge by Plasmodium sporozoites or a sterile response. Such identified antigenic fusion polypeptides may thus constitute active ingredients suitable for the design of a vaccine candidate, in particular a vaccine suitable for a human host.

The present invention relates to new specific 6-6 or 5-6 fused bicyclic compounds comprising pyrimidine or pyridine useful in the prevention and / or treatment of infectious diseases. In particular, the present invention relates to a compound of formula (I) wherein: Ar1 is a (C5-C11)arylene or (C5-C11)heteroarylene group, X is —CH—, —S—, —NR5 or —N—, Y is —CH—, —NR5—S— or —NR6—CH2—, T is —CH— and Q is —CH— or T is —N— and Q is —CR10— or —N—, provided that one or two of X, Q and Y comprise a heteroatom, and with the proviso that, at least one of R1, R2, and, if present, R5 or R6, contains a group —NH-Alk-NR3R4. The inventors showed that compounds of formula (I) present an activity against both W2 and 3D7 Plasmodium falciparum strains, an activity against T. brucei brucei but also an activity against SARS-CoV-2 virus, and that they are positive for G4 recognition. The invention also relates to the preparation process and to the therapeutic uses of the compounds of formula (I).

Herein is described a method devised to cryopreserve mosquito eggs, viable upon subsequent thawing. The method reproducibly yields >25% hatched first instar larvae of Anopheles-species mosquitoes from cryopreserved eggs. The majority of hatched larvae continue to develop normally (87% pupation), through to adults (98%, 50% of which are female) which subsequently blood feed and produce viable second generation embryos that also develop normally. Adult mosquitoes obtained from cryopreserved embryos are able to be infected with Plasmodium falciparum gametocytes and produce salivary gland sporozoites in similar numbers to control mosquitoes.

The invention relates to galactose-containing agents for the prophylaxis and / or alleviation and / or healing of infections with sporozoa of the genus Plasmodium and malaria disease caused thereby in a patient or potential patient.

The present invention provides a fragment of plasmodium circumsporozoite protein according to SEQ ID NO: 1, for example for use in a malaria vaccine. The present invention also provides nucleic acids encoding a fragment of plasmodium circumsporozoite protein according to SEQ ID NO: 1, compositions comprising a fragment of plasmodium circumsporozoite protein according to SEQ ID NO: 1 and antibodies binding to a fragment of plasmodium circumsporozoite protein according to SEQ ID NO: 1. The antibodies according to the present invention bind specifically to P. falciparum sporozoites and may be used in the treatment and / or prevention of malaria.

The invention discloses a plasmodium vivax SNP (Single Nucleotide Polymorphism) molecular marker and application thereof in tracing. The SNP molecular marker provided by the invention can be used for effectively identifying plasmodium vivax in the inland of China. According to the invention, one SNP molecular marker is identified and obtained through a PCR method, and then plasmodium vivax is traced. According to the invention, plasmodium vivax DNA traceability is carried out by adopting a PCR method based on the SNP molecular marker, the method has the characteristics of convenience and rapidness, the SNP molecular marker stably and widely exists in plasmodium vivax genome DNA, and large-scale popularization of the traceability technology is facilitated.

The invention relates to application of a TNF-alpha antibody in preparation of a medicine for inhibiting plasmodium transmission, and belongs to the technical field of malaria prevention. In order to solve the problems that in the prior art, the drug resistance of chemical drugs is prominent, efficient vaccines are lacked, and mosquito-stage transmission blocking means are insufficient, TNF-alpha antibodies are injected into plasmodium infected hosts to block binding of host TNF-alpha and mosquito wengen receptors, so that IMD channels are activated, expression of anti-malarial effector factors TEP1 is promoted, and development of plasmodium in mosquito bodies is inhibited; meanwhile, the occurrence rate of host cerebral malaria is reduced, and the transmission blocking effect can be synergistically enhanced by combining with the anti-Pfs25 antibody. The method is accurate in targeting, specifically intervenes a TNF-alpha signal channel, and avoids non-specific damage; dual protection: synchronously blocking mosquito propagation and preventing severe malaria of a host; the blocking efficiency is remarkably improved by combining with the anti-Pfs25 antibody, and a new strategy is provided for malaria prevention and control.

The invention provides a plasmodium infection stage detection method and system, and the method comprises the steps: obtaining a plasmodium image, carrying out the marking of the plasmodium image, determining a corresponding infection stage, constructing a preliminary data set through the marked plasmodium image, and carrying out the data processing of the preliminary data set, and determining a plasmodium infection stage image data set; constructing a ResNet-based plasmodium infection stage detection framework, and designing a convolution block attention module in a feature fusion module of the ResNet framework; constructing a mixed loss function to optimize the detection architecture; and training the constructed detection architecture according to the plasmodium infection stage image data set to determine a target plasmodium infection stage detection architecture. The method solves the problem that in the prior art, a plasmodium infection stage detection method for accurately and rapidly identifying irregular forms of plasmodium in different infection stages is lacked.

The invention belongs to the technical field of plasmodium falciparum pigment detection, and particularly relates to a plasmodium falciparum pigment content detection method and application thereof. The plasmodium falciparum pigment content detection method comprises the following steps: resuspending erythrocytes infected by plasmodium falciparum by using a solvent, adding saponin, uniformly mixing, standing, centrifuging, and collecting precipitate to obtain plasmodium falciparum coarse precipitate. And centrifuging the plasmodium falciparum coarse precipitate, and collecting the precipitate to obtain the plasmodium falciparum precipitate. And re-suspending the plasmodium falciparum precipitate by using an SDS solution, repeatedly centrifuging and collecting the precipitate until the absorbance value at 400nm in the centrifuged supernatant is zero, collecting the precipitate, adding the SDS solution and a NaOH solution for dissolving, detecting the absorbance value at the wavelength of 400nm, and calculating to obtain the content of the plasmodium falciparum pigment. The plasmodium falciparum pigment content detection method does not need complex technologies such as Raman spectrum and magnetic separation, and the pigment level and forming ability of plasmodium can be rapidly screened and determined.

The invention belongs to the technical field of molecular biological detection, and relates to a polypeptide for detecting asymptomatic infection of plasmodium vivax malaria and application. The polypeptide for detecting the asymptomatic infection of the malaria of the plasmodium vivax is an amino acid sequence as shown in SEQ ID No.1, or a homologous sequence which is subjected to substitution, deletion or insertion of one or more amino acids or has the sequence similarity greater than 75%. The polypeptide has an amino acid sequence as shown in SEQ ID No. 1. The polypeptide SEQ ID No.1 in the invention specifically detects asymptomatic tertian malaria infection, and can effectively deal with tertian malaria input threats in the Burmese border area. Meanwhile, the polypeptide can be coated in a detection tool of a rapid detection kit, and the tool has the characteristics of portability, high efficiency, low cost and the like, and is suitable for field sample detection in a malaria prevalence area.

The invention relates to mir-331-3p as a biomarker for predicting malaria transmission and application of the mir-331-3p, and belongs to the technical field of biology. The invention aims to provide a more accurate biomarker, and solves the technical defect that the existing index cannot effectively evaluate the malaria spreading risk. The invention provides a host-derived miR-331-3p (miR-331-3p) used as a malaria transmission prediction marker. The detection kit containing the marker is constructed by detecting the expression level of miR-331-3p in host serum and combining the characteristic that the miR-331-3p regulates and controls the development of plasmodium in mosquito bodies in a cross-species manner. Compared with traditional gametophyte detection, the method has the advantages that the sensitivity is improved, and the technical bottleneck that the gametophyte rate and the transmission capacity are unhooked is broken through; 2) non-invasive detection is realized, and only trace serum samples are needed; and 3) establishing a host-medium bidirectional regulation and control model, and providing a new target spot for malaria transmission blocking.

The invention discloses a plasmodium vivax SNP (Single Nucleotide Polymorphism) molecular marker combination and application thereof in tracing. The 15 SNP molecular markers provided by the invention are mutually independent, and the molecular marker combination can effectively identify Chinese inland plasmodium vivax. According to the invention, 15 SNP molecular markers are obtained through identification by a high-throughput gene mass spectrum chip method, and an SNPs information group of plasmodium vivax is formed by the obtained effective SNPs sites, so that the plasmodium vivax is traced. According to the invention, plasmodium vivax DNA traceability is carried out based on a gene mass spectrum chip method adopted by the SNPs molecular markers, and the method has the characteristics of high throughput and rapidness, and the 15 SNPs molecular markers stably and widely exist in plasmodium vivax genome DNA, so that large-scale popularization of the traceability technology is facilitated.

The invention relates to chimeric Plasmodium antigenic polypeptides derived from pre-erythrocytic (PE) antigens and associated in a fusion polypeptide. In particular, the invention relates to antigenic fusion polypeptides of malaria parasites wherein said antigenic polypeptides exhibit a protective effect, especially that of eliciting a protective immune response in a host against challenge by Plasmodium sporozoites or a sterile response. Such identified antigenic fusion polypeptides may thus constitute active ingredients suitable for the design of a vaccine candidate, in particular a vaccine suitable for a human host.

The compositions and methods are described for generating an immune response to a Plasmodium antigen. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to malaria by expressing the Plasmodium antigen in the subject to which the MVA vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and / or treat malaria.

The invention relates to the technical field of biology, in particular to construction and application of an lnc30 overexpression strain. Comprising the following steps: (1) carrying out enzyme digestion on an original plasmid pLN-ENR-GFP by utilizing Hind III restriction enzyme, recovering a larger fragment, and then carrying out fragment self-connection to obtain a pBSD plasmid; (2) construction of a pBSD-30 plasmid: carrying out PCR (Polymerase Chain Reaction) to obtain and purify a U6 promoter gene, and connecting the gene between a 5'cloning site ApaI and a 3 'cloning site Avr II of the PLN-ENR-GFP plasmid; the method comprises the following steps: synthesizing an lnc30 full-length gene, and connecting the lnc30 gene between a 5'cloning site Avr II and a 3 'cloning site Afl II of a PLN-ENR-GFP plasmid; the lnc30 is connected with a U6 promoter, so that high expression of the lnc30 in cells is ensured. Experiments prove that lnc30 overexpression can significantly enhance the growth advantage of plasmodium falciparum and the ability of merozoite invading erythrocytes and participate in regulation of the erythroid stage development process of plasmodium, but knock-down of lnc30 may cause death of plasmodium, which indicates that the lnc30 overexpression strain is successfully constructed and can be used for research of a plasmodium falciparum gene expression regulation mechanism, and the lnc30 overexpression strain can be used for preparing the plasmodium falciparum gene expression regulation mechanism. The method is used for screening and researching drugs for inhibiting growth and development of plasmodium falciparum, and has remarkable scientific value and application prospect.

The present disclosure provides compositions (e.g., pharmaceutical compositions) and related technology (e.g., components thereof and / or methods related thereto) for the delivery of malaria protein antigens. Among other things, the present disclosure provides polyribonucleotides encoding malaria protein antigens.

Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (Burkholderia pseudomallei, Borrelia burgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Francisella tularensis, human Herpes virus 1 and 2, Mycobacterium tuberculosis, Plasmodium falciparum, and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.

The present disclosure relates to synthetic Plasmodium reticulocyte binding protein 2b (mRBP2b) antigens that have improved properties such as thermal stability, as well as the use of these antigens to detect a Plasmodium infection in a diagnostic device or for use in a vaccine.

The invention belongs to the field of molecular biology and biomedical engineering, and particularly relates to a primer group for plasmodium genus and species identification and a colorimetric detection method based on loop-mediated isothermal amplification (LAMP). The primer group comprises a primer group of plasmodium and a specific primer group between plasmodium species; wherein the primer group (Pan-Plasmodium (Pan)) of the plasmodium is sequence information (5 '-3'), and the specific details are recorded in the specification. And through the optimally designed LAMP reaction system and the chromogenic reaction of the magnesium ion by-product and the pH indicator, the identification result of the sample can be judged, the detection efficiency is improved, and the visual instant detection of the plasmodium species is realized. Compared with existing microscope detection and rapid diagnosis test paper, the test paper has the advantages of short detection time, high sensitivity, strong specificity and the like, and provides a new technical means for accurate diagnosis, prevention and control of malaria.

Disclosed is an integrated or combined device for a saliva test for at least two analytes comprising a sampling member, an intermediate section and an immunolabeling section comprising a plurality of antibodies for the specific binding of the analytes and a plurality of second antibodies for detecting the analytes, which analytes are the histidine-rich protein (HRP) and the lactate dehydrogenase (LDH) protein of Plasmodium sp..